Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing.
Royer-Bertrand B, Torsello M, Rimoldi D, El Zaoui I, Cisarova K, Pescini-Gobert R, Raynaud F, Zografos L, Schalenbourg A, Speiser D, Nicolas M, Vallat L, Klein R, Leyvraz S, Ciriello G, Riggi N, Moulin AP, Rivolta C. Royer-Bertrand B, et al. Among authors: rimoldi d. Am J Hum Genet. 2016 Nov 3;99(5):1190-1198. doi: 10.1016/j.ajhg.2016.09.008. Epub 2016 Oct 13. Am J Hum Genet. 2016. PMID: 27745836 Free PMC article.
Genomic and transcriptomic landscape of conjunctival melanoma.
Cisarova K, Folcher M, El Zaoui I, Pescini-Gobert R, Peter VG, Royer-Bertrand B, Zografos L, Schalenbourg A, Nicolas M, Rimoldi D, Leyvraz S, Riggi N, Moulin AP, Rivolta C. Cisarova K, et al. Among authors: rimoldi d. PLoS Genet. 2020 Dec 31;16(12):e1009201. doi: 10.1371/journal.pgen.1009201. eCollection 2020 Dec. PLoS Genet. 2020. PMID: 33383577 Free PMC article.
Lack of BRAF mutations in uveal melanoma.
Rimoldi D, Salvi S, Liénard D, Lejeune FJ, Speiser D, Zografos L, Cerottini JC. Rimoldi D, et al. Cancer Res. 2003 Sep 15;63(18):5712-5. Cancer Res. 2003. PMID: 14522889
Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways Inhibition.
El Zaoui I, Bucher M, Rimoldi D, Nicolas M, Kaya G, Pescini Gobert R, Bedoni N, Schalenbourg A, Sakina E, Zografos L, Leyvraz S, Riggi N, Rivolta C, Moulin AP. El Zaoui I, et al. Among authors: rimoldi d. Invest Ophthalmol Vis Sci. 2019 Jun 3;60(7):2764-2772. doi: 10.1167/iovs.18-26508. Invest Ophthalmol Vis Sci. 2019. PMID: 31247083
Broad and Conserved Immune Regulation by Genetically Heterogeneous Melanoma Cells.
Neubert NJ, Tillé L, Barras D, Soneson C, Baumgaertner P, Rimoldi D, Gfeller D, Delorenzi M, Fuertes Marraco SA, Speiser DE. Neubert NJ, et al. Among authors: rimoldi d. Cancer Res. 2017 Apr 1;77(7):1623-1636. doi: 10.1158/0008-5472.CAN-16-2680. Epub 2017 Jan 19. Cancer Res. 2017. PMID: 28104684
Expression of CALLA/CD10 on human melanoma cells.
Carrel S, Zografos L, Schreyer M, Rimoldi D. Carrel S, et al. Among authors: rimoldi d. Melanoma Res. 1993 Oct;3(5):319-23. doi: 10.1097/00008390-199310000-00003. Melanoma Res. 1993. PMID: 8292887 Review.
Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.
Romano E, Pradervand S, Paillusson A, Weber J, Harshman K, Muehlethaler K, Speiser D, Peters S, Rimoldi D, Michielin O. Romano E, et al. Among authors: rimoldi d. Clin Cancer Res. 2013 Oct 15;19(20):5749-57. doi: 10.1158/1078-0432.CCR-13-0661. Epub 2013 Aug 15. Clin Cancer Res. 2013. PMID: 23948972
137 results